Wegovy Pill Attracts New GLP-1 Patients, Study Shows

More than a third of patients who started taking Novo Nordisk’s Wegovy pill had never used a GLP-1 drug before, according to a new study. The findings suggest the oral version is drawing new patients into the fast-growing weight-loss market. As a result, analysts say the pill may expand demand rather than simply shift users from injections.

Researchers from Truveta analyzed medical records from 8,762 U.S. patients who began taking the pill. They found that 36% had not previously used any GLP-1 therapy. In contrast, about 21% had used injectable Wegovy before. Another 15.8% had switched from Zepbound, an injectable made by Eli Lilly.

The results indicate that the pill is not just cannibalizing older products. Instead, it appears to reach patients who avoided injectable treatments. Many patients dislike needles or find injections inconvenient. Therefore, a daily pill offers a simpler option for some people seeking weight-loss therapy.

GLP-1 drugs mimic a gut hormone that helps regulate blood sugar and appetite. Doctors originally used them to treat type 2 diabetes. However, drugmakers later developed higher-dose versions for obesity treatment. In recent years, demand has surged as clinical trials showed significant weight loss.

Until recently, patients could only access GLP-1 treatments through injections. However, Novo Nordisk introduced the first widely available oral version for weight loss late last year. The company already markets injectable Wegovy and the diabetes drug Ozempic. With the pill, it aims to strengthen its position in the obesity market.

Prescription data suggest strong early interest. Analysts tracking weekly trends reported tens of thousands of prescriptions within the first weeks of launch. This rapid uptake underscores the appeal of an oral option. Moreover, it reflects sustained consumer interest in weight-loss medicines.

The study also offers insight into who is taking the pill. Most early users were women, accounting for more than 70% of patients. In addition, nearly three-quarters of patients were white. Researchers also found that most lived in urban areas.

Age trends stood out as well. More than one-third of users were between 45 and 59 years old. Meanwhile, nearly 38% were aged 60 or older. These figures suggest that middle-aged and older adults are leading early adoption. Over time, however, demographics could shift as awareness spreads.

Cost remains an important factor in access. The pill carries a lower introductory price than many injectable GLP-1 drugs. Therefore, some patients may see it as a more affordable entry point. Even so, insurance coverage varies widely across plans. Out-of-pocket expenses could still limit broader uptake.

At the same time, competition is intensifying. Eli Lilly is developing its own oral weight-loss treatment. If regulators approve that product, patients could soon have multiple pill options. Consequently, rivalry between drugmakers may drive further innovation and marketing efforts.

Novo Nordisk is also expanding its product lineup. The company recently announced plans to offer Wegovy in vial form. This move could provide additional flexibility in dosing and distribution. As manufacturers increase supply, they hope to avoid the shortages that plagued earlier launches.

The broader GLP-1 market has grown rapidly in the United States. Prescriptions now account for a meaningful share of total pharmacy volume. Because obesity affects millions of Americans, drugmakers see a large and durable market opportunity. Investors have rewarded companies that lead in this space.

Still, experts caution that early data may not predict long-term trends. Some injectable users could switch to the pill over time. Others may try the pill first and later move to injections for greater effectiveness. Patient preferences and physician guidance will shape those decisions.

Furthermore, researchers will monitor whether new patients stay on therapy. GLP-1 drugs often require long-term use to maintain weight loss. Therefore, adherence rates will influence overall sales and health outcomes. Side effects, including nausea and gastrointestinal discomfort, could also affect persistence.

For now, the study highlights the pill’s ability to attract first-time users. More than one in three early patients had no prior experience with GLP-1 medicines. That figure suggests the oral format lowers barriers for some individuals. As competition grows and awareness increases, the obesity drug market could enter another phase of expansion.

In the coming months, analysts will track switching patterns, prescription growth, and insurance coverage changes. They will also assess how new entrants affect pricing. Although uncertainties remain, the early data point to strong demand for a needle-free alternative. Consequently, the Wegovy pill may reshape how patients begin weight-loss treatment.